Maryland State Retirement & Pension System Raises Stake in TG Therapeutics, Inc. $TGTX

Maryland State Retirement & Pension System lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 2.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,853 shares of the biopharmaceutical company’s stock after acquiring an additional 936 shares during the quarter. Maryland State Retirement & Pension System’s holdings in TG Therapeutics were worth $1,434,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in TGTX. NBC Securities Inc. increased its position in TG Therapeutics by 82,300.0% during the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 823 shares during the period. GAMMA Investing LLC lifted its position in TG Therapeutics by 77.7% during the first quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 1,986 shares during the period. Grimes & Company Inc. acquired a new stake in TG Therapeutics during the first quarter worth about $241,000. Cordant Inc. acquired a new position in shares of TG Therapeutics in the 1st quarter valued at $102,000. Finally, Praxis Investment Management Inc. purchased a new position in TG Therapeutics in the first quarter valued at $231,000. 58.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TGTX has been the subject of several recent analyst reports. The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 price target for the company in a report on Thursday, July 10th. HC Wainwright assumed coverage on TG Therapeutics in a report on Monday, October 6th. They set a “buy” rating and a $60.00 price target on the stock. B. Riley upped their price objective on TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $49.00.

TG Therapeutics Price Performance

TGTX stock opened at $33.76 on Friday. The business’s 50-day moving average is $31.51 and its two-hundred day moving average is $35.21. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. TG Therapeutics, Inc. has a 1 year low of $21.65 and a 1 year high of $46.48. The firm has a market capitalization of $5.36 billion, a P/E ratio of 91.24 and a beta of 1.97.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. During the same quarter last year, the firm earned $0.04 EPS. The company’s revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. Analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.64% of the stock is currently owned by corporate insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.